Elicio Therapeutics Welcomes Marc J. Wolfgang as Chief Technology Officer
Elicio Therapeutics, Inc. (Nasdaq: ELTX), renowned for developing groundbreaking immunotherapies for cancer treatment, has announced that Marc J. Wolfgang, M.S., will be its new Chief Technology Officer (CTO). This strategic appointment heralds a significant leap in the company’s mission to innovate and accelerate its pipeline of immunotherapy solutions.
Executive Experience of Marc J. Wolfgang
With an impressive background spanning over three decades in the biopharmaceutical sector, Marc J. Wolfgang brings invaluable expertise in manufacturing, CMC strategy, development, quality control, and supply chain management. His most recent role was as Senior Vice President of Technical Development and Operations at Sail Biomedicines, where he adeptly managed all facets of development, manufacturing, analytical, and quality functions.
His career also includes pivotal positions at industry giants such as BioNTech, where he was Vice President of U.S. Manufacturing and oversaw critical operations in cell and gene therapy. He has contributed significantly to building and scaling manufacturing frameworks and spearheading global technology transfers throughout his tenure at organizations like Cerulean Pharma and Biogen.
Strategic Alignment with Elicio's Goals
Robert T. Connelly, President and CEO of Elicio, emphasized the importance of Wolfgang’s appointment, stating, “Marc is an exceptional CMC strategy and operations leader with deep experience guiding innovative therapeutic platforms from early development through commercial readiness.” As Elicio prepares for significant late-stage development of its lead program ELI-002 7P, Wolfgang’s extensive knowledge of cell therapy and RNA-based medicines will play a crucial role in driving these efforts forward.
Focus on Innovation and Infrastructure Development
In his new role, Wolfgang expressed excitement about joining Elicio, particularly as the company anticipates key developments in the ELI-002 7P program. He remarked on the impactful potential of Elicio’s lymph node-targeted platform, which aims to enhance and direct immune responses effectively.
Educational Background and Contributions
Marc J. Wolfgang holds a Master’s degree in Chemistry from Montclair State University and a Bachelor’s degree in Biology (Genetics) from Pennsylvania State University. His investment in education extends to a Biopharma Executive Leadership Certificate from Babson College. Furthermore, he has made significant contributions to the field as a former chairman of the Nanomedicines Alliance and through collaborations with prominent regulatory bodies like the FDA and NIH.
About Elicio Therapeutics
Elicio Therapeutics, Inc. (Nasdaq: ELTX) is a pioneering biotechnology company committed to advancing novel immunotherapies targeting high-prevalence cancers, such as mKRAS-positive pancreatic and colorectal cancers. Through its innovative Amphiphile (AMP) technology, Elicio seeks to enhance T cell education and activation compared to traditional immunization strategies, focusing on promoting sustained cancer immunotherapy.
The company’s ELI-002 program is particularly noteworthy as it represents an off-the-shelf immunotherapy candidate targeting prevalent KRAS mutations responsible for about 25% of solid tumors. The company is conducting a randomized clinical trial for ELI-002 in patients with mKRAS-positive pancreatic cancer who are at high risk of relapse following standard therapy. The initial findings reported during the AMPLIFY-201 Phase 1 studies showcased promising outcomes, including median recurrence-free and overall survival rates.
Future Plans and Pipeline Enhancements
Elicio is also looking to extend ELI-002’s applications to other cancer types, including mKRAS positive lung cancer. Additionally, the company is poised to unveil further off-the-shelf therapeutic candidates, such as ELI-007 and ELI-008, aimed at treating BRAF-driven cancers and p53 hotspot mutations, respectively. Elicio’s commitment to delivering effective and accessible immunotherapy continues to drive its innovative efforts.
Frequently Asked Questions
Who is Marc J. Wolfgang?
Marc J. Wolfgang is the newly appointed Chief Technology Officer of Elicio Therapeutics, bringing extensive experience in biopharmaceutical leadership.
What role does Elicio Therapeutics focus on?
Elicio Therapeutics focuses on developing novel immunotherapies to treat various types of cancer, leveraging innovative technologies.
What is ELI-002?
ELI-002 is an off-the-shelf immunotherapy candidate targeting common KRAS mutations, currently undergoing clinical trials.
What is the significance of the Amphiphile technology?
The Amphiphile technology enhances T cell activation, aiming to create more effective cancer treatments compared to traditional methods.
How does Elicio intend to expand its product offerings?
Elicio plans to expand its immunotherapy portfolio to include additional candidates like ELI-007 and ELI-008 targeting other cancer mutations.
